{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:20:16Z","timestamp":1791062416149,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":39,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003459.pub3","type":"reference-entry","created":{"date-parts":[[2012,12,6]],"date-time":"2012-12-06T18:52:23Z","timestamp":1354819943000},"source":"Crossref","is-referenced-by-count":19,"title":["Methotrexate for induction of remission in refractory Crohn's disease"],"prefix":"10.1002","author":[{"given":"John WD","family":"McDonald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Tsoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"10.1002\/14651858.CD003459.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1590-8658(03)00372-4","article-title":"Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study","volume":"35","author":"Ardizzone","year":"2003","journal-title":"Digestive and Liver Disease"},{"issue":"27","key":"10.1002\/14651858.CD003459.pub3-BIB2|cit2","first-page":"1724","article-title":"Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial","volume":"46","author":"Arora","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"10.1002\/14651858.CD003459.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.gastro.2008.05.061","article-title":"A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003459.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mat\u00e9-Jim\u00e9nez","year":"2000","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD003459.pub3-BIB6|cit6","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"American Journal of Gastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD003459.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00042737-200601000-00003","article-title":"Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study","volume":"18","author":"Schr\u00f6der","year":"2006","journal-title":"European Journal of Gastroenterology and Hepatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003459.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"S799","DOI":"10.1016\/S0016-5085(12)63102-3","article-title":"Assessment of the efficacy of oral methotrexate in conjunction with infliximab therapy for the treatment of inflammatory bowel disease","volume":"142","author":"Afzali","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003459.pub3-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/BF01296109","article-title":"Low-dose oral methotrexate in refractory inflammatory bowel disease","volume":"38","author":"Baron","year":"1993","journal-title":"Digestive Diseases and Sciences"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003459.pub3-BIB10|cit10","first-page":"A659","article-title":"The efficacy of long term intramuscular methotrexate in difficult to treat Crohn's disease","volume":"136","author":"Clark","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003459.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1873-9946(12)60259-1","article-title":"Methotrexate as a third-line therapy after thiopurine and anti-TNF failure in Crohn's disease","volume":"6","author":"Diaz-Saa","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1002\/14651858.CD003459.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1046\/j.1365-2036.1999.00667.x","article-title":"A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis","volume":"13","author":"Egan","year":"1999","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003459.pub3-BIB13|cit13","first-page":"A662","article-title":"Efficacy and safety of methotrexate therapy in inflammatory bowel disease. The Madrid experience","volume":"136","author":"Gonzalez-Lama","year":"2009","journal-title":"Gastroenterology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003459.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"A403","DOI":"10.1136\/gutjnl-2012-302514d.259","article-title":"Inflammatory bowel disease III: PWE-259\u2005The efficacy of methotrexate in Crohn's disease: a clinical perspective","volume":"61","author":"Gordon-Walker","year":"2012","journal-title":"Gut"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003459.pub3-BIB15|cit15","first-page":"E152","article-title":"Efficacy of methotrexate in the treatment of pediatric Crohn's disease - Single center report","volume":"52","author":"Hojsak","year":"2011","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1002\/14651858.CD003459.pub3-BIB16|cit16","first-page":"2552","article-title":"Methotrexate as possible treatment of refractory chronic inflammatory bowel disease","volume":"138","author":"Houben","year":"1992","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"key":"10.1002\/14651858.CD003459.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.7326\/0003-4819-110-5-353","article-title":"Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease","volume":"110","author":"Kozarek","year":"1989","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD003459.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2036.2010.04569.x","article-title":"Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab","volume":"33","author":"Laharie","year":"2011","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003459.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.0953-0673.1996.00309.x","article-title":"Methotrexate for the treatment of refractory Crohn's disease","volume":"10","author":"L\u00e9mann","year":"1996","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003459.pub3-BIB20|cit20","first-page":"1730","article-title":"Methotrexate in Crohn's disease: long-term efficacy and toxicity","volume":"95","author":"L\u00e9mann","year":"2000","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub3-BIB22|cit21","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S1873-9946(09)60116-1","article-title":"Results from a prospective study combining infliximab, surgery, and methotrexate in severe fistulising ano-perineal Crohn's disease","volume":"3","author":"Roumegu\u00e8re","year":"2009","journal-title":"Journal of Crohn's and Colitis"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub3-BIB21|cit22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ibd.21405","article-title":"Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study","volume":"17","author":"Roumegu\u00e8re","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003459.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1016\/S0016-5085(11)61124-4","article-title":"Effectiveness and tolerability of maintenance methotrexate therapy in Crohn's disease patients: Analysis of a referral hospital-based 10-years intercept cohort","volume":"140","author":"Seinen","year":"2011","journal-title":"Gastroenterology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD003459.pub3-BIB24|cit24","first-page":"A663","article-title":"Parenteral methotrexate for Crohn's disease: 9 years experience in a district general hospital","volume":"136","author":"Taylor","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1002\/14651858.CD003459.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00054725-199902000-00002","article-title":"Methotrexate in refractory Crohn's disease","volume":"5","author":"Vandeputte","year":"1999","journal-title":"Inflammatory Bowel Diseases"},{"issue":"12","key":"10.1002\/14651858.CD003459.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1200\/JCO.1988.6.12.1882","article-title":"Pharmacokinetics of subcutaneous methotrexate","volume":"6","author":"Balis","year":"1988","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003459.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/gut.26.2.146","article-title":"Prognosis in Crohn's disease - based on result from a regional patient group from the country of Copenhagen","volume":"26","author":"Binder","year":"1985","journal-title":"Gut"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/art.1780330112","article-title":"Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis","volume":"33","author":"Brooks","year":"1990","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD003459.pub3-BIB29|cit29","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Chande","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003459.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0009-9236(99)70119-0","article-title":"Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease","volume":"65","author":"Egan","year":"1999","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"10","key":"10.1002\/14651858.CD003459.pub3-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/39.10.1102","article-title":"Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?","volume":"39","author":"Griffith","year":"2000","journal-title":"Rheumatology"},{"issue":"7650","key":"10.1002\/14651858.CD003459.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"8167","key":"10.1002\/14651858.CD003459.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003459.pub3-BIB34|cit34","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration"},{"issue":"3","key":"10.1002\/14651858.CD003459.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis and Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD003459.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/rheumatology\/39.7.812","article-title":"Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription","volume":"39","author":"Lorenzi","year":"2000","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD003459.pub3-BIB37|cit37","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000297.pub2","article-title":"Cyclosporine for induction of remission in Crohn's disease","author":"McDonald","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003459.pub3-BIB38|cit38","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011) The Cochrane Collaboration"},{"issue":"4","key":"10.1002\/14651858.CD003459.pub3-BIB39|cit39","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003459.pub2","article-title":"Methotrexate for induction of remission in refractory Crohn\u2019s disease","author":"Alfadhli","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003459.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003459.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:21:01Z","timestamp":1628529661000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003459.pub3"}},"subtitle":[],"editor":[{"given":"John WD","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003459.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD003459.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2012,12,12]]}}}